List of Excipients in Branded Drug VOQUEZNA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Phathom Pharmaceuticals Inc	VOQUEZNA	vonoprazan fumarate	81520-100	ASCORBIC ACID	2032-05-03
Phathom Pharmaceuticals Inc	VOQUEZNA	vonoprazan fumarate	81520-100	CELLULOSE, MICROCRYSTALLINE	2032-05-03
Phathom Pharmaceuticals Inc	VOQUEZNA	vonoprazan fumarate	81520-100	CROSCARMELLOSE SODIUM	2032-05-03

VOQUEZNA Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Voquezna, the U.S. brand for vonoprazan, is a potassium-competitive acid blocker marketed by Phathom Pharmaceuticals. Its commercial opportunity rests on rapid and durable acid suppression, simplified Helicobacter pylori treatment, and formulation differentiation from proton-pump inhibitors. The excipient strategy should prioritize tablet robustness, moisture control, rapid dissolution, dose flexibility, and co-pack compatibility rather than extended-release technology.

The most attractive development opportunities are pediatric dosage forms, lower-cost generic-ready formulations, taste-masked liquid or dispersible products, and differentiated combination packs for H. pylori eradication. The principal commercial risk is that excipient innovation may create limited market protection unless it is tied to clinically meaningful performance, a protected manufacturing process, or a formulation patent.

What is Voquezna and which formulations are commercially approved?

Voquezna contains vonoprazan fumarate, a potassium-competitive acid blocker that inhibits the gastric H+/K+-ATPase. It is approved in the United States for erosive esophagitis, maintenance of healed erosive esophagitis, relief of heartburn associated with erosive gastroesophageal reflux disease, and treatment of H. pylori infection in combination with antibiotics.[1]

Product	Active ingredients	Primary use	Dosage form
Voquezna 10 mg	Vonoprazan fumarate	Erosive esophagitis maintenance and heartburn relief	Film-coated tablet
Voquezna 20 mg	Vonoprazan fumarate	Healing of erosive esophagitis and selected GERD treatment	Film-coated tablet
Voquezna Triple Pak	Vonoprazan, amoxicillin, clarithromycin	H. pylori eradication	Co-packaged tablets and capsules
Voquezna Dual Pak	Vonoprazan and amoxicillin	H. pylori eradication	Co-packaged tablets and capsules

The U.S. Food and Drug Administration approved vonoprazan-containing products for H. pylori treatment in 2022 and approved Voquezna for erosive GERD indications in 2023.[1,2] Phathom Pharmaceuticals commercializes the products in the United States under an agreement with Takeda Pharmaceutical, which developed vonoprazan internationally.[3]

What excipients are used in Voquezna tablets?

The Voquezna label identifies inactive ingredients used in the tablet core and film coating. Public labeling should be treated as the controlling source for the marketed formulation because formulation composition may differ across strengths, manufacturing sites, and geographic markets.[1]

The formulation design is consistent with an immediate-release, film-coated oral tablet. Its excipient functions are likely to include:

Excipient function	Commercial purpose
Dilution and tablet mass control	Allows accurate manufacture of a low-dose active ingredient
Binder function	Improves granule and tablet mechanical strength
Disintegration	Promotes rapid tablet breakup and drug release
Lubrication	Reduces sticking and ejection force during compression
Film coating	Supports appearance, handling, identification, and swallowability
Color protection	Differentiates dosage strengths and reduces dispensing errors

Vonoprazan is administered at relatively low milligram strengths compared with many solid oral drugs. That creates a high excipient-to-active ratio and increases the importance of content uniformity, blend segregation control, and powder-flow management.

A formulation developer seeking a comparable product would need to reproduce dissolution and bioequivalence performance, not merely match the qualitative excipient list. Changes in particle size, granulation, lubricant level, coating weight, compression force, or manufacturing equipment can alter tablet disintegration and drug release.

How should an excipient strategy for Voquezna be designed?

The optimal strategy is a platform approach covering the 10 mg and 20 mg tablets, the H. pylori combination packs, and future pediatric or patient-friendly presentations.

1. Prioritize immediate-release performance

Vonoprazan does not require an extended-release delivery system for its approved uses. The principal technical target is rapid and reproducible dissolution. Excessive hydrophobic lubricant, dense granulation, or an overly robust film coat could delay release and create bioequivalence risk.

A development program should control:

• Tablet disintegration time
• Dissolution across physiologic pH conditions
• Content uniformity
• Tablet hardness and friability
• Moisture uptake
• Stability under accelerated conditions
• Compatibility with co-packaged antibiotics

2. Manage low-dose content uniformity

Low-dose products can be vulnerable to segregation during blending, transfer, and compression. A direct-compression formulation may offer a shorter process, but wet granulation or dry granulation can improve uniformity and flow when the active ingredient has poor handling characteristics.

The commercial value of an excipient platform increases if the same process can support both 10 mg and 20 mg strengths. A common formulation architecture can reduce validation costs, simplify supply planning, and lower the risk of strength-specific manufacturing failures.

3. Control moisture and chemical stability

Vonoprazan products are likely to require controlled moisture exposure during manufacturing and storage. Moisture can affect API stability, tablet hardness, dissolution, and the performance of co-packaged antibiotics.

Relevant commercial options include:

• High-barrier blister packaging
• Desiccant-supported bottles
• Moisture-protective film coating
• Low-water-activity excipient systems
• Tight control of granulation and drying endpoints

Packaging is not technically an excipient, but it is part of the same product-protection strategy. A superior moisture barrier can support longer shelf life without changing the tablet composition.

4. Preserve antibiotic compatibility in combination packs

The Triple Pak and Dual Pak create a packaging and adherence problem that is different from the standalone GERD tablet. The product must protect multiple dosage forms while communicating the dosing schedule clearly.

Excipient-related opportunities include:

• Color-coded tablets and capsules
• Unit-dose blister cards
• Calendarized dose packaging
• Printed administration instructions
• Packaging that separates antibiotics from moisture-sensitive components
• Reduced tablet burden through optimized co-pack configuration

A co-pack does not necessarily require a new excipient composition to create commercial differentiation. Packaging engineering, dosing instructions, and stability data can provide the more valuable product advantage.

What formulation patents could protect a Voquezna follow-on product?

Formulation protection could cover more than the active pharmaceutical ingredient. Potential claim categories include:

1. Specific excipient ratios.
2. Granulation processes.
3. Particle-size distributions.
4. Dissolution profiles.
5. Film-coating systems.
6. Moisture-protective packaging.
7. Fixed-dose or co-packaged antibiotic regimens.
8. Dispersible, orally disintegrating, liquid, or pediatric formulations.
9. Manufacturing controls that produce defined impurity or stability profiles.

The strongest formulation claims generally connect composition to a measurable technical result, such as improved stability, faster dissolution, improved content uniformity, or reduced food effect. Generic claims covering routine use of common excipients are more vulnerable to enablement, obviousness, and design-around attacks.

For a follow-on developer, a formulation patent should be supported by comparative data against the marketed tablet. Useful evidence includes stability under high humidity, dissolution comparisons, impurity formation, tablet robustness, and pharmacokinetic performance.

When does Voquezna lose exclusivity?

Voquezna has regulatory, patent, and commercial exclusivity layers.

Exclusivity layer	Relevance
New chemical entity exclusivity	May restrict submission of an ANDA for the active ingredient during the statutory period, subject to FDA classification and product-specific rules
Listed patents	May delay approval or create litigation exposure for an ANDA
Formulation patents	Can protect dosage form, excipient system, manufacturing process, or packaging
Method-of-use patents	May create certification and litigation issues for approved indications
Regulatory exclusivity for combination products	May differ from exclusivity for vonoprazan monotherapy
Trade secrets	Can protect process parameters and manufacturing know-how but do not block independent development

FDA approved U.S. vonoprazan products beginning in 2022, with the standalone Voquezna GERD product approved in 2023.[1,2] The exact date for generic entry depends on the applicable FDA exclusivity designation, Orange Book patent listings, Paragraph IV litigation, court decisions, and any settlement terms.

An ANDA applicant may challenge listed patents through a Paragraph IV certification. The branded sponsor can file an infringement action, which may trigger a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and litigation developments.[4]

What is the Orange Book status of Voquezna?

The FDA Orange Book is the controlling source for active U.S. patents and exclusivity associated with approved Voquezna products.[4] Orange Book status can change as patents are listed, delisted, corrected, or associated with particular strengths and indications.

The relevant diligence questions are:

• Which patents are listed against Voquezna 10 mg and 20 mg?
• Are the listed patents composition, formulation, method-of-use, or drug-delivery patents?
• Which patents expire first?
• Do the patents apply to standalone tablets, combination packs, or both?
• Have any ANDA applicants submitted Paragraph IV certifications?
• Has Phathom filed patent litigation against an ANDA applicant?
• Do settlement agreements provide a licensed entry date?

Without a confirmed current Orange Book extract and litigation docket, patent expiration dates should not be treated as fixed commercial-entry dates. A patent expiry alone does not guarantee launch if other listed patents, regulatory exclusivity, manufacturing constraints, or settlement restrictions remain relevant.

Which companies are challenging or competing with Voquezna?

Voquezna competes with both conventional acid-suppression products and alternative H. pylori regimens.

Competitive group	Examples	Main competitive issue
Proton-pump inhibitors	Omeprazole, esomeprazole, lansoprazole, pantoprazole	Low cost, broad generic availability
Other potassium-competitive acid blockers	Vonoprazan products outside the U.S.	Potential price and access competition
H. pylori combination products	Talicia and generic component regimens	Adherence, pill burden, resistance coverage
Generic antibiotic combinations	Amoxicillin, clarithromycin, metronidazole-based regimens	Low acquisition cost
Future generic vonoprazan	ANDA products after regulatory and patent barriers	Direct price erosion

Voquezna’s strongest commercial position is in patients who need predictable acid suppression, patients with erosive esophagitis, and H. pylori patients for whom a prepackaged regimen may improve adherence. Its main weakness is price competition from inexpensive generic PPIs and individually prescribed antibiotics.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue opportunities at four levels.

Patient-friendly dosage forms

A pediatric or geriatric formulation could use:

• Orally disintegrating tablets
• Dispersible tablets
• Taste-masked granules
• Oral suspensions
• Unit-dose sachets

Taste masking would be central because vonoprazan and antibiotic components may create unpleasant sensory characteristics. Ion-exchange resins, polymeric coatings, lipid barriers, and multiparticulate systems are potential approaches, subject to dissolution and bioavailability requirements.

Differentiated combination products

Excipient and packaging suppliers can support an improved H. pylori product through dose organization, moisture protection, and administration simplicity. The commercial value may come from adherence data rather than a new chemical composition.

Generic manufacturing platforms

A reliable direct-compression or granulation platform could reduce production cost and simplify development of generic vonoprazan tablets. Excipient suppliers with global regulatory files, low-nitrosamine risk, consistent particle-size distributions, and strong supply continuity would have an advantage.

Lifecycle management

Potential lifecycle products include lower-dose maintenance tablets, pediatric presentations, orally disintegrating tablets, and formulations optimized for patients with swallowing difficulties. Each product would require FDA approval and evidence supporting dose accuracy, stability, dissolution, and, where applicable, bioequivalence.

How strong is the Voquezna patent estate?

The commercial strength of the estate depends on the interaction among active-ingredient patents, product-specific patents, method-of-use claims, regulatory exclusivity, and manufacturing know-how.

The active ingredient is not the sole source of protection. A broader estate could include:

• Vonoprazan composition claims
• Solid-state or salt-form claims
• Tablet formulation claims
• H. pylori treatment claims
• GERD treatment claims
• Manufacturing-process claims
• Combination-pack or regimen claims

Formulation patents are most valuable when they cover a necessary performance attribute that is difficult to design around. A patent limited to a common excipient combination may provide less durable protection than a patent tied to a defined dissolution profile, stability advantage, or manufacturing result.

What generic launch scenarios exist for Voquezna?

Three launch scenarios are commercially relevant.

Scenario 1: Patent-led delay

FDA approval of an ANDA is delayed by listed patents, statutory exclusivity, litigation, or a settlement agreement. The branded product retains broad pricing power.

Scenario 2: Limited or licensed entry

A generic launches on a negotiated date or with a restricted label. Erosion is initially limited, especially if the generic excludes patented indications.

Scenario 3: Broad generic competition

Multiple ANDA products enter after regulatory and patent barriers expire. Price erosion accelerates, and commercial value shifts toward manufacturing cost, formulary access, and combination-pack convenience.

The highest-risk products are standalone 10 mg and 20 mg tablets because they are relatively straightforward to replicate. Combination packs may retain more differentiation if packaging, stability, and adherence data are protected or commercially valued.

Key Takeaways

• Voquezna is an immediate-release vonoprazan product with approved GERD and H. pylori uses.
• The core excipient priorities are content uniformity, rapid dissolution, moisture control, tablet robustness, and antibiotic compatibility.
• The strongest lifecycle opportunities are pediatric, orally disintegrating, dispersible, liquid, and adherence-oriented combination products.
• Excipient changes alone may have limited commercial value unless supported by clinical, stability, manufacturing, or patent advantages.
• Generic risk depends on FDA exclusivity, Orange Book listings, Paragraph IV certifications, litigation, settlements, and the number of approved entrants.
• Packaging and co-pack engineering may create greater practical value for H. pylori products than changes to the tablet core.
• A durable formulation estate should connect excipient composition to measurable performance results.

FAQs

Can Voquezna be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet is a plausible lifecycle product, but development would need to address taste masking, dose uniformity, rapid dispersion, moisture sensitivity, mechanical strength, and bioequivalence.

Which excipients are most important for generic vonoprazan tablets?

The most important excipient attributes are low segregation risk, reliable flow, controlled lubrication, rapid disintegration, low moisture reactivity, and compatibility with the vonoprazan fumarate active ingredient.

Can a new excipient combination block generic Voquezna entry?

It can create additional patent protection if the formulation produces a non-obvious and measurable technical result. A routine substitution of one conventional excipient for another is less likely to provide durable protection.

Is Voquezna commercially stronger than a proton-pump inhibitor?

Voquezna has potential clinical advantages in speed and consistency of acid suppression, but generic PPIs have a major cost and formulary advantage. Commercial performance depends on reimbursement, physician adoption, diagnosis, and evidence of treatment benefit.

Does a Voquezna combination pack eliminate adherence problems?

No. A co-pack can simplify dispensing and reduce regimen complexity, but adherence still depends on dosing frequency, tolerability, patient understanding, antibiotic resistance, and access.

References

1. U.S. Food and Drug Administration. (2023). Voquezna prescribing information.
2. U.S. Food and Drug Administration. (2022). FDA approves vonoprazan-based regimens for Helicobacter pylori infection.
3. Phathom Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.